Zobrazeno 1 - 10
of 79
pro vyhledávání: '"B. ANGELELLI"'
Autor:
D'AMBRA, MARIELDA, CASADEI, RICCARDO, CALCULLI, LUCIA, BARBIERI, ERSILIA, DI MARCO, MARIACRISTINA, REGA, DANIELA, RICCI, CLAUDIO, MACCHINI, MARINA, SERRA, CARLA, LEGA, STEFANIA, R. Pezzilli, B. Angelelli, A. Guido
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::f0138d069efbb7e46348ae0cb0570ee7
http://hdl.handle.net/11585/122630
http://hdl.handle.net/11585/122630
Autor:
A. GUIDO, M. MICUCCI, M. D'AMBRA, C. RICCI, D. REGA, R. PEZZILLI, L. CALCULLI, DI MARCO, MARIACRISTINA, B. ANGELELLI, F. SPERANDI, C. SERRA, D. SANTINI, CASADEI, RICCARDO, CECCONI, AGNESE, BUNKHEILA, FEISAL, CAMMELLI, SILVIA, BARBIERI, ENZA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::2591e1d25bb54b67b079de906f3c6984
http://hdl.handle.net/11585/78836
http://hdl.handle.net/11585/78836
Autor:
M. Tognetto, Fabio Gelsomino, S. Restuccia, Francesco Massari, D. Grilli, B. Angelelli, Andrea Ardizzoni, C. Puggioli
Publikováno v:
Annals of Oncology. 27:iv115
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7c353a4b645a0cd91eefbd35e7a00ce
https://doi.org/10.1093/annonc/mdw345.28
https://doi.org/10.1093/annonc/mdw345.28
Autor:
G. Fiorentini, Pietro Ruggieri, A. F. Mavrogenis, B. Angelelli, Costantino Errani, Giulio Rossi, Eugenio Rimondi, Tommaso Bartalena, Mario Mercuri, Cristina Tranfaglia, Federica Ciccarese
The authors present the experience of a single institution with selective arterial embolisation for primary and metastatic bone tumours. A total of 365 patients were treated with 454 embolisation procedures from December 2002 to April 2010. Embolisat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55cd4ed8935f201332c68baefc1ffdf4
http://hdl.handle.net/11585/125890
http://hdl.handle.net/11585/125890
Publikováno v:
Journal of Chemotherapy. 5:47-51
Forty-two patients affected by either stage III and IV ovarian cancer with residual tumor after surgery or recurrent ovarian cancer entered a phase II study of the combination carboplatin 300 mg/m2 and cyclophosphamide 600 mg/m2 every 28 days. Thirty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1bddb787e82d0ace8adfa1e62a21f0a
https://doi.org/10.1080/1120009x.1993.11739209
https://doi.org/10.1080/1120009x.1993.11739209
Autor:
A, Martoni, E, Mini, C, Pinto, A L, Gentile, S, Nobili, P, Dentico, A, Marino, S, Scicolone, B, Angelelli, T, Mazzei
Publikováno v:
Anticancer research. 23(1B)
The combination of Oxaliplatin (OXA) and Raltitrexed (RTX) may represent a more convenient regimen as compared with OXA + 5-FU with Folinic acid (FA) modulation regimens. The present trial has been designed to explore the activity and tolerability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::291f9444d8773f3a39ae77bf5b2b694f
https://pubmed.ncbi.nlm.nih.gov/12680168
https://pubmed.ncbi.nlm.nih.gov/12680168
Publikováno v:
Anticancer research. 19(1B)
Induction chemotherapy, consisting of 3 courses of cisplatin (30 mg/m2/i.v. 1st and 2nd day), epirubicin (30 mg/m2/i.v. 1st and 2nd day), etoposide (75 mg/m2/i.v. 1st and 2nd day) and bleomycin (15 mg/i.v. 1st and 2nd day), prior to radical hysterect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::90ae323075b594020ee867aaf432d324
https://pubmed.ncbi.nlm.nih.gov/10216490
https://pubmed.ncbi.nlm.nih.gov/10216490
Autor:
A, Martoni, E, Piana, E, Strocchi, B, Angelelli, M, Guaraldi, C, Zamagni, C M, Camaggi, F, Pannuti
Publikováno v:
Anticancer research. 18(4B)
The 5HT3 receptor antagonist Granisetron (GRA) is available on the market as a 1 mg vial in USA and as a 3 mg vial in Europe. This study aimed to compare the two i.v. doses of GRA (3 mg vs 1 mg), both of which combined with Dexamethasone (DEX) (20 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::34e6f893d3f4a9df4de08686db490e21
https://pubmed.ncbi.nlm.nih.gov/9713464
https://pubmed.ncbi.nlm.nih.gov/9713464
Publikováno v:
Frontiers in bioscience : a journal and virtual library. 2
Majority of ovarian cancer patients have advanced disease (stage III or IV) at diagnosis and the prognosis of these patients is poor in spite of aggressive surgery. Therefore chemotherapy has gained a fundamental role in the therapeutic approach of o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4f6c5f3cd0d591a83db38eea4b6430f2
https://pubmed.ncbi.nlm.nih.gov/9159262
https://pubmed.ncbi.nlm.nih.gov/9159262
Publikováno v:
European journal of cancer (Oxford, England : 1990). (1)
The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f313014b9fb5421a9b4b6df133476de5
https://pubmed.ncbi.nlm.nih.gov/8695248
https://pubmed.ncbi.nlm.nih.gov/8695248